• Moderna Begins Phase 1 Study Of Its Epstein-Barr Virus Vaccine Candidate

    Source: NASDAQ US Markets / 05 Jan 2022 07:43:07   America/New_York

    (RTTNews) - Moderna, Inc. (MRNA) said the first participant has been dosed in the phase 1 study of mRNA-1189, the company's Epstein-Barr Virus vaccine candidate. The phase 1 randomized, observer-blind, placebo-controlled study of mRNA-1189 will be conducted at approximately 15 si https://www.nasdaq.com/articles/moderna-begins-phase-1-study-of-its-epstein-barr-virus-vaccine-candidate
Share on,